Top

Published in:

01-06-2012 | Editorial

New treatments of pancreatic neuroendocrine tumors: why using them? How to use them?

Authors: Eric Raymond, Philippe Ruszniewski

Published in: Targeted Oncology | Issue 2/2012

Excerpt

Neuroendocrine tumor has long been considered as a rare tumor, although its prevalence makes it one of the most frequent gastrointestinal malignancies [1]. In the eighties, streptozotocin-based chemotherapy allowed substantial improvements in the management of advanced pancreatic neuroendocrine tumors (PNETs) [2, 3]. Subsequently, somatostatin analogues were shown to be useful for the control of symptomatic PNETs and also able to delay tumor progression in slow-growing midgut carcinoids [4]. …

Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, Abdalla EK, Fleming JB, Vauthey JN, Rashid A, Evans DB (2008) One hundred years after “Carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 26:3063–3072PubMedCrossRef

Moertel CG, Hanley JA, Johnson LA (1980) Streptozocin alone compared with streptozocin plus fluorouracil in the treatment of advanced islet-cell carcinoma. N Engl J Med 303:1189–1194PubMedCrossRef

Moertel CG, Lefkopoulo M, Lipsitz S, Hahn RG, Klaassen D (1992) Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma. N Engl J Med 326:519–523PubMedCrossRef

Rinke A, Müller H-H, Schade-Brittinger C, Klose K-J, Barth P, Wied M, Mayer C, Aminossadati B, Pape U-F, Bläker M, Harder J, Arnold C, Gress T, Arnold R, PROMID Study Group (2009) Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol 27:4656–4663PubMedCrossRef

Raymond E, Dahan L, Raoul J-L, Bang Y-J, Borbath I, Lombard-Bohas C, Valle J, Metrakos P, Smith D, Vinik A, Chen J-S, Hörsch D, Hammel P, Wiedenmann B, van Cutsem E, Patyna S, Lu DR, Blanckmeister C, Chao R, Ruszniewski P (2011) Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 364:501–513PubMedCrossRef

Yao JC, Shah MH, Ito T, Bohas CL, Wolin EM, van Cutsem E, Hobday TJ, Okusaka T, Capdevila J, de Vries EGE, Tomassetti P, Pavel ME, Hoosen S, Haas T, Lincy J, Lebwohl D, Öberg K, RAD001 in Advanced Neuroendocrine Tumors Third Trial RADIANT-3 Study Group (2011) Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 364:514–523PubMedCrossRef

Raymond E, Faivre S, Hammel P, Ruszniewski P (2009) Sunitinib paves the way for targeted therapies in neuroendocrine tumors. Target Oncol 4:253–254PubMedCrossRef

Kulke MH, Siu LL, Tepper JE, Fisher G, Jaffe D, Haller DG, Ellis LM, Benedetti JK, Bergsland EK, Hobday TJ, Van Cutsem E, Pingpank J, Oberg K, Cohen SJ, Posner MC, Yao JC (2011) Future directions in the treatment of neuroendocrine tumors: consensus report of the National Cancer Institute Neuroendocrine Tumor clinical trials planning meeting. J Clin Oncol 29:934–943PubMedCrossRef

Teulé A and Casanovas O (2012) Relevance of angiogenesis in neuroendocrine tumors. Target Oncol. doi:10.1007/s11523-012-0217-x

10.

Raymond E, Hammel P, Dreyer C, Maatescu C, Hentic O, Rusniewski P, Faivre S (2012) Sunitinib in pancreatic neuroendocrine tumors. Target Oncol. doi:10.1007/s11523-012-0220-2

11.

Benavent M, de Miguel MJ, Garcia-Carbonero R (2012) New targeted agents in gastroenteropancreatic neuroendocrine tumors. Target Oncol. doi:10.1007/s11523-012-0218-9

12.

Zappa M, Abdel-Rehim M, Hentic O, Vullierme MP, Ruszniewski P, Vilgrain V (2012) Liver-directed therapies in liver metastases from neuroendocrine tumors of the gastrointestinal tract. Target Oncol. doi:10.1007/s11523-012-0219-8

13.

Faivre S et al. (2012) Choi in PNETs. Target Oncol (in press)

Title: New treatments of pancreatic neuroendocrine tumors: why using them? How to use them?
Authors: Eric Raymond
Philippe Ruszniewski
Publication date: 01-06-2012
Publisher: Springer-Verlag
Published in: Targeted Oncology / Issue 2/2012
Print ISSN: 1776-2596
Electronic ISSN: 1776-260X
DOI: https://doi.org/10.1007/s11523-012-0222-0

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 2/2012

Sunitinib in pancreatic neuroendocrine tumors

Liver-directed therapies in liver metastases from neuroendocrine tumors of the gastrointestinal tract

Relevance of angiogenesis in neuroendocrine tumors

Pazopanib therapy for cerebellar hemangioblastomas in von Hippel–Lindau disease

Expression of metastasis-associated protein 2 (MTA2) might predict proliferation in non-small cell lung cancer

New targeted agents in gastroenteropancreatic neuroendocrine tumors

Keynote webinar | Spotlight on antibody–drug conjugates in cancer